Artiva Biotherapeutics, Inc.

(a) 8-K Events

On November 10, 2025, Neha Krishnamohan notified Artiva Biotherapeutics, Inc. (the “Company”) of her decision to resign from her position as Chief Financial Officer and principal financial and accounting officer of the Company, effective no later than December 31, 2025 (the “Separation Date”). Ms. Krishnamohan’s resignation was not the result of any dispute or disagreement with the Company. The Company plans to conduct a search for Ms. Krishnamohan’s replacement.

In connection with Ms. Krishnamohan’s separation from the Company, she and the Company entered into a transition and separation agreement, dated as of November 11, 2025 (the “Separation Agreement”), pursuant to which Ms. Krishnamohan will: (i) remain as an active employee until the Separation Date, and provide certain transition assistance to the Company; (ii) release and waive all claims against the Company; (iii) subject to a consulting agreement, to be effective as of the day following the Separation Date (the “Consulting Agreement”), serve as a non-employee consultant to the Company through no later than February 28, 2026 (the “Consulting Period”); (iv) receive compensation in the amount of at least $20,000 per month for consulting services during the Consulting Period; (v) as a severance benefit, remain eligible to receive her annual bonus for calendar year 2025; and (vi) continue to vest in the stock option and restricted stock unit awards that were granted to her pursuant to the Company’s 2020 Equity Incentive Plan and 2024 Equity Incentive Plan until the conclusion of the Consulting Period. The foregoing separation benefits are conditioned upon, among other things, Ms. Krishnamohan’s compliance with the terms of the Separation Agreement.

The foregoing description of the Separation Agreement does not purport to be complete and is qualified in its entirety by reference to the full text of the Separation Agreement, a copy of which will be filed as an exhibit to a subsequent filing with the Securities and Exchange Commission.

(c) Trading Arrangements

During the quarter ended September 30, 2025, no director or officer adopted orterminated any Rule 10b5-1 trading arrangement or any non-Rule 10b5-1 trading arrangement (as such terms are defined pursuant to Item 408(a) of Regulation S-K).